RDN2150 (TFA)
RDN2150 (Compound 25) TFA is a ZAP-70 inhibitor (IC50: 14.6 nM) . RDN2150 TFA covalently binds to the C346 residue of ZAP-70. RDN2150 TFA inhibits the expression of CD25 and CD69, and inhibits CD4+ T cell activation. RDN2150 TFA can be used for research of psoriasis[1].
Product Specifications
UNSPSC
12352005
Target
Tyrosinase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/rdn2150-tfa.html
Concentration
10mM
Purity
99.80
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C1=C(N=C(N2C1=NC=C2)NCC3=CC(NC(C=C)=O)=C(C=C3)Cl)NC4=CC(OC)=C(C=C4)N5CCOCC5)N.OC(C(F)(F)F)=O
Molecular Formula
C30H30ClF3N8O6
Molecular Weight
691.06
References & Citations
[1]Rao D, et al. Discovery and Structural Optimization of Covalent ZAP-70 Kinase Inhibitors against Psoriasis. J Med Chem. 2023 Aug 18.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Maf, NT (Maf, Maf2, Transcription factor Maf, Proto-oncogene c-Maf, V-maf musculoaponeurotic fibrosarcoma oncogene homolog) (MaxLight 550) discontinued